BioCentury
ARTICLE | Product R&D

A1M for preeclampsia

How A1M Pharma is going upstream in preeclampsia

April 21, 2016 7:00 AM UTC

A poor understanding of disease biology and a challenging development pathway have kept most drug developers away from the serious pregnancy complication preeclampsia, but A1M Pharma AB has a new approach with a first-in-class therapy that intervenes in the disease process upstream of the dangerous symptoms. Using a recombinant form of A1M - a scavenger of heme and reactive oxygen species (ROS) - the company believes it can protect against tissue damage and provide a treatment that avoids preterm delivery.

Last month, the company announced its first therapeutic candidate, RMC-035, a recombinant form of A1M based on research from Lund University that showed the protein is up-regulated in the placenta in response to preeclampsia-induced oxidative stress...